China Resources Pharmaceutical Group Limited (03320) has announced its interim results for the six months ended June 30, 2026, revealing revenue of HK$134.4576 billion, representing a 2% year-on-year increase, while profit attributable to equity shareholders grew 5.3% to HK$2.187 billion. Basic earnings per share stood at HK$0.35, with an interim dividend of HK$0.087 per share declared.

During the first half of 2026, the company's three primary business segments鈥攑harmaceutical manufacturing, pharmaceutical distribution, and drug retail and others鈥攁ccounted for 16.2%, 79.1%, and 4.7% of total revenue, respectively.

Within the reporting period, the pharmaceutical manufacturing segment generated segment revenue of HK$24.4447 billion, reflecting a modest 1.5% decline year-on-year. The gross profit margin for this segment reached 60.3%, marking an improvement of 1.0 percentage point compared to the same period last year.

Meanwhile, the pharmaceutical distribution segment achieved segment revenue of HK$110.9948 billion, up 2.5% from the previous year, with a gross margin of 5.7%, representing a slight decrease of 0.2 percentage points year-on-year.

In the drug retail segment, revenue reached HK$6.3372 billion, posting a robust 14.9% increase. Notably, the high-value drug direct-to-patient (DTP) business generated approximately HK$4.83 billion in revenue, surging 28.6% year-on-year. The retail segment's gross margin improved to 6.3%, up 0.2 percentage points from the prior-year period.